Saturday 17 October 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024. Insiders bought in the last twelve months.
21.10
0.10
+0.48%
Follow APLM
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.25 | 1.39 | 0.97 | 0.96 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
10.15% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.17 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.10) | (0.06) | 0.34 | 0.19 | |
Intangible Assets out of Total Assets |
0.14 | 0.13 | 0.02 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | — | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(16.01) | (28.76) | (7.58) | (10.32) | |
Working Capital |
15.76 | 2.87 | (0.34) | (0.27) | |
Capital Expenditures |
(0.02) | (0.02) | 0.05 | 0.05 | |
Net Current Asset Value |
14.65 | 2.03 | (5.39) | (3.85) | |
| Other line items | |||||
Quick Ratio |
2.05 | 1.32 | 0.89 | 0.88 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Assets |
70.23 | 44.79 | 41.25 | 31.05 | |
Average Common Equity |
8.36 | (221.63) | 25.65 | 19.02 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026